Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, Board Director of Levicept and Chair of Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Let’s not forget the first scientific publication that proposed the idea of electrical vagus nerve stimulation in the prototypic immune-mediated inflammatory disease, rheumatoid arthritis: Nat Rev Rheumatol, 2009 vol. 5(4) pp. 229-32. The cholinergic anti-inflammatory pathway:…
How the brain talks to the immune system
This diagram shows the inflammatory reflex - a neural circuit where the brain regulates inflammation through the vagus nerve. It’s how psychological stress, inflammation, and immune activity stay linked.
1️⃣ The signal starts in the brain…
Thanks to the independent panel of senior industry experts for selecting Candel’s CAN-2409 in prostate cancer for the prestigious SCRIP Award in the category’Best Oncology R&D Advance’!
We’re thrilled to announce that Candel has been honored at the Scrip Awards 2025!
This recognition celebrates our successful phase 3 study of CAN-2409 in localized prostate cancer.
Thank you to @Citeline for this honor.
https://www.citeline.com/en/awards/scripawards
Dr. Glen Gejerman spoke to @UrologyTimes about Candel’s phase 3 trial results for CAN-249 in localized intermediate- to high-risk prostate cancer, presented at ASTRO 2025.
Tune into this insightful video to hear more.
https://www.urologytimes.com/view/glen-gejerman-md-highlights-phase-3-data-on-can-2409-in-localized-prostate-cancer
#ICYMI - Our Q3 financial results highlighted the significant progress across our cancer immunotherapy pipeline. From clinical advancements to strategic financing, we’re positioning Candel for continued growth.
Read more here: https://www.proactiveinvestors.com/companies/news/1082445/candel-therapeutics-highlights-3q-milestones-across-cancer-immunotherapy-pipeline-1082445.html
#CADL
